The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.
More Latest News
October 23, 2020
Click here to view the full requirements for the Nonresident Sterile Compounding renewal for Nonresident Pharmacies and Outsourcing Facilities. Continue reading
October 2, 2020
Emergency Order DOH No. 20-014 allows licensed pharmacists and registered pharmacy interns to administer FDA approved vaccines to individuals, including those under 18 years of age. Continue reading